← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
BBCQ
Bleichroeder Acquisition Corp. II
Valuation N/A
Financial Services
Price$9.79
Model IV—
P/IV—
Limited data — see page
BBD
BANK BRADESCO
Valuation N/A
Financial Services Risk 40 · Elevated
Price$3.60
Model IV—
P/IV—
Limited data — see page
BBDO
BANK BRADESCO
Valuation N/A
Financial Services Risk 33 · Moderate
Price$3.20
Model IV—
P/IV—
Limited data — see page
BBN
BlackRock Taxable Municipal Bond Trust
Valuation N/A
Unknown
Price$15.22
Model IV—
P/IV—
Limited data — see page
BBOT
BridgeBio Oncology Therapeutics, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$4.95
Model IV—
P/IV—
Limited data — see page
BBUC
Brookfield Business Corp
Valuation N/A
Industrials Risk 46 · Elevated
Price$25.87
Model IV—
P/IV—
Limited data — see page
BBVA
BANCO BILBAO VIZCAYA ARGENTARIA, S.A.
Valuation N/A
Financial Services Risk 33 · Moderate
Price$29.55
Model IV—
P/IV—
Limited data — see page
BCAB
BioAtla, Inc.
Valuation N/A
Healthcare Risk 36 · Moderate
Price$1.50
Model IV—
P/IV—
Market implies +65.3%/yr vs model +15.0% · above model
BCAC
Brookline Capital Acquisition Corp II
Valuation N/A
Financial Services
Price$4.93
Model IV—
P/IV—
Limited data — see page
BCAR
D. Boral ARC Acquisition I Corp.
Valuation N/A
Technology
Price$3.81
Model IV—
P/IV—
Limited data — see page
BCAT
BlackRock Capital Allocation Term Trust
Valuation N/A
Unknown
Price$14.80
Model IV—
P/IV—
Limited data — see page
BCAX
Bicara Therapeutics Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$22.81
Model IV—
P/IV—
Limited data — see page
BCDA
BioCardia, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$1.19
Model IV—
P/IV—
Market implies +64.2%/yr vs model +15.0% · above model
BCSS
Bain Capital GSS Investment Corp.
Valuation N/A
Financial Services
Price$10.29
Model IV—
P/IV—
Limited data — see page
BCTX
BriaCell Therapeutics Corp.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$3.63
Model IV—
P/IV—
Limited data — see page
BCTXL
BriaCell Therapeutics Corp.
Valuation N/A
Healthcare Risk 28 · Moderate
Price$0.95
Model IV—
P/IV—
Limited data — see page
BCTXZ
BriaCell Therapeutics Corp.
Valuation N/A
Healthcare Risk 39 · Moderate
Price$0.14
Model IV—
P/IV—
Limited data — see page
BCV
BANCROFT FUND LTD
Valuation N/A
Unknown
Price$24.52
Model IV—
P/IV—
Limited data — see page
BCX
BlackRock Resources & Commodities Strategy Trust
Valuation N/A
Unknown
Price$12.92
Model IV—
P/IV—
Limited data — see page
BCYC
BICYCLE THERAPEUTICS PLC
Valuation N/A
Healthcare Risk 39 · Moderate
Price$3.86
Model IV—
P/IV—
Market implies +19.2%/yr vs model +18.2% · in line
BDCI
BTC Development Corp.
Valuation N/A
Financial Services
Price$10.16
Model IV—
P/IV—
Limited data — see page
BDJ
BlackRock Enhanced Equity Dividend Trust
Valuation N/A
Unknown
Price$9.69
Model IV—
P/IV—
Limited data — see page
BDX
BECTON DICKINSON & CO
Valuation N/A
Healthcare Risk 47 · Elevated
Price$177.85
Model IV—
P/IV—
Market implies +3.3%/yr vs model +5.4% · in line
BE
Bloom Energy Corp
Valuation N/A
Technology Risk 61 · High
Price$257.05
Model IV—
P/IV—
Market implies +48.2%/yr vs model +21.9% · above model
BEAG
Bold Eagle Acquisition Corp.
Valuation N/A
Financial Services
Price$10.70
Model IV—
P/IV—
Limited data — see page
BEAGR
Bold Eagle Acquisition Corp.
Valuation N/A
Financial Services
Price$0.18
Model IV—
P/IV—
Limited data — see page
BEAM
Beam Therapeutics Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$23.99
Model IV—
P/IV—
Market implies +43.2%/yr vs model +28.1% · above model
BEAT
HeartBeam, Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$0.41
Model IV—
P/IV—
Limited data — see page
BEBE
TGE Value Creative Solutions Corp
Valuation N/A
Financial Services
Price$10.05
Model IV—
P/IV—
Limited data — see page
BEEM
Beam Global
Valuation N/A
Technology Risk 42 · Elevated
Price$1.43
Model IV—
P/IV—
Limited data — see page
BELFA
BEL FUSE INC /NJ
Valuation N/A
Technology
Price$190.92
Model IV—
P/IV—
Limited data — see page
BELFB
BEL FUSE INC /NJ
Valuation N/A
Technology
Price$250.36
Model IV—
P/IV—
Limited data — see page
BENF
Beneficient
Valuation N/A
Financial Services Risk 42 · Elevated
Price$1.06
Model IV—
P/IV—
Limited data — see page
BETA
BETA Technologies, Inc.
Valuation N/A
Industrials Risk 37 · Moderate
Price$20.68
Model IV—
P/IV—
Market implies +65.2%/yr vs model +50.0% · above model
BETR
Better Home & Finance Holding Co
Valuation N/A
Financial Services Risk 55 · Elevated
Price$12.95
Model IV—
P/IV—
Market implies +26.5%/yr vs model +15.0% · above model
BFAM
BRIGHT HORIZONS FAMILY SOLUTIONS INC.
Valuation N/A
Consumer Defensive Risk 47 · Elevated
Price$66.87
Model IV—
P/IV—
Market implies -3.0%/yr vs model +12.5% · below model
BFLX
Cann American Corp.
Valuation N/A
Basic Materials Risk 42 · Elevated
Price$25.84
Model IV—
P/IV—
Market implies +82.7%/yr vs model +5.0% · above model
BFLY
Butterfly Network, Inc.
Valuation N/A
Healthcare Risk 35 · Moderate
Price$7.33
Model IV—
P/IV—
Market implies +66.0%/yr vs model +11.8% · above model
BFRG
BullFrog AI Holdings, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.48
Model IV—
P/IV—
Market implies +66.4%/yr vs model +15.0% · above model
BFRI
Biofrontera Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$1.55
Model IV—
P/IV—
Market implies -11.3%/yr vs model +14.8% · below model
BGB
Blackstone Strategic Credit 2027 Term Fund
Valuation N/A
Unknown
Price$11.22
Model IV—
P/IV—
Limited data — see page
BGC
BGC Group, Inc.
Valuation N/A
Financial Services Risk 46 · Elevated
Price$12.17
Model IV—
P/IV—
Limited data — see page
BGDE
Big Digital Energy, Inc.
Valuation N/A
Financial Services Risk 45 · Elevated
Price$6.79
Model IV—
P/IV—
Market implies -10.7%/yr vs model +2.0% · below model
BGH
BARINGS GLOBAL SHORT DURATION HIGH YIELD FUND
Valuation N/A
Unknown
Price$13.84
Model IV—
P/IV—
Limited data — see page
BGIN
BGIN BLOCKCHAIN Ltd
Valuation N/A
Financial Services Risk 29 · Moderate
Price$1.82
Model IV—
P/IV—
Market implies +42.6%/yr vs model +2.0% · above model
BGL
Blue Gold Ltd
Valuation N/A
Basic Materials Risk 33 · Moderate
Price$0.21
Model IV—
P/IV—
Market implies +18.8%/yr vs model +5.0% · above model
BGR
BlackRock Energy & Resources Trust
Valuation N/A
Unknown
Price$17.63
Model IV—
P/IV—
Limited data — see page
BGSI
Boyd Group Services Inc.
Valuation N/A
Industrials Risk 37 · Moderate
Price$90.40
Model IV—
P/IV—
Limited data — see page
BGT
BLACKROCK FLOATING RATE INCOME TRUST
Valuation N/A
Unknown
Price$10.99
Model IV—
P/IV—
Limited data — see page
BGX
Blackstone Long-Short Credit Income Fund
Valuation N/A
Unknown
Price$10.62
Model IV—
P/IV—
Limited data — see page
BGY
BlackRock Enhanced International Dividend Trust
Valuation N/A
Unknown
Price$5.82
Model IV—
P/IV—
Limited data — see page
BH
Biglari Holdings Inc.
Valuation N/A
Consumer Cyclical
Price$372.67
Model IV—
P/IV—
Limited data — see page
BHAV
BHAV Acquisition Corp
Valuation N/A
Financial Services
Price$10.02
Model IV—
P/IV—
Limited data — see page
BHAVR
BHAV Acquisition Corp
Valuation N/A
Financial Services
Price$0.15
Model IV—
P/IV—
Limited data — see page
BHK
BLACKROCK CORE BOND TRUST
Valuation N/A
Unknown
Price$8.55
Model IV—
P/IV—
Limited data — see page
BHV
BLACKROCK VIRGINIA MUNICIPAL BOND TRUST
Valuation N/A
Unknown
Price$12.67
Model IV—
P/IV—
Limited data — see page
BHVN
Biohaven Ltd.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$12.71
Model IV—
P/IV—
Limited data — see page
BHYP
Bitwise Hyperliquid ETF
Valuation N/A
Financial Services Risk 33 · Moderate
Price$45.78
Model IV—
P/IV—
Limited data — see page
BIAF
bioAffinity Technologies, Inc.
Valuation N/A
Industrials Risk 31 · Moderate
Price$7.95
Model IV—
P/IV—
Market implies +81.5%/yr vs model +15.0% · above model
BIDU
Baidu, Inc.
Valuation N/A
Technology Risk 54 · Elevated
Price$91.40
Model IV—
P/IV—
Limited data — see page